- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.08. | Liminatus Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.08. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.07. | Liminatus plans to invest up to $500 million in BNB coin | 4 | Investing.com | ||
| 28.07. | Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative | 2 | GlobeNewswire (USA) | ||
| LIMINATUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 25.07. | Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies | 259 | GlobeNewswire (Europe) | LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 24.07. | Liminatus Pharma stock soars after engaging Digital Offering for capital raise | 2 | Investing.com | ||
| 24.07. | Pre-market Movers: Sadot Group, Community Health Systems, Liminatus Pharma, MaxLinear, Incannex Healthcare | 719 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.10 A.M. ET).In the Green Liminatus Pharma, Inc. (LIMN) is up over 25% at... ► Artikel lesen | |
| 24.07. | Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy | 1 | GlobeNewswire (USA) | ||
| 22.07. | Liminatus gains amid review to consider digital assets for treasury management | 2 | Seeking Alpha | ||
| 22.07. | Liminatus Pharma explores digital assets for treasury management | 1 | Investing.com | ||
| 22.07. | Liminatus Pharma Inc.: Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy | 176 | GlobeNewswire (Europe) | LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 11.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.07. | Liminatus Pharma bildet Konsortium für Bauchspeicheldrüsenkrebs-Diagnosekit | 2 | Investing.com Deutsch | ||
| 03.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Liminatus Pharma files to sell 6.9M shares of common stock | 2 | Seeking Alpha | ||
| 24.06. | Liminatus Pharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 24.06. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | 796 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| 05.06. | Liminatus Pharma stock gains on regaining compliance with Nasdaq | 1 | Seeking Alpha | ||
| 05.06. | Liminatus Pharma-Aktien steigen nach Nasdaq-Compliance-Meldung | 5 | Investing.com Deutsch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TENAYA THERAPEUTICS | 1,690 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen | |
| QIAGEN | 39,190 | +3,97 % | ROUNDUP/Aktien Frankfurt Eröffnung: Moderate Verluste - Richtungssuche | FRANKFURT (dpa-AFX) - Nach den leichten Gewinnen vom Vortag haben die Anleger am deutschen Aktienmarkt am Donnerstag wieder etwas auf die Bremse getreten. "Die Richtungssuche geht weiter", konstatierte... ► Artikel lesen | |
| BIONTECH | 87,15 | +3,75 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
| EVOTEC | 6,336 | +2,39 % | Evotec: Aktie in Problemen? - Aixtron, Circus, Commerzbank, Gerresheimer und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,095 | 0,00 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
| TOURMALINE BIO | 47,860 | +0,08 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
| LENZ THERAPEUTICS | 49,050 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Commercial Product Availability of VIZZ in the United States | VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is... ► Artikel lesen | |
| PALISADE BIO | 1,285 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock | ||
| MINERALYS THERAPEUTICS | 39,820 | 0,00 % | Mineralys auf Stifel-Forum: Strategischer Fahrplan für Blutdruckmittel Lorundrostat | ||
| IMMUNOME | 11,340 | 0,00 % | Where Immunome Stands With Analysts | ||
| PRIME MEDICINE | 5,590 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates | -- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept for Prime Editing; plan to have regulatory interactions... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 38,640 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
| AVIDITY BIOSCIENCES | 43,010 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| 89BIO | 14,690 | 0,00 % | F. Hoffmann-La Roche Ltd: Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash | Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB)... ► Artikel lesen | |
| VALNEVA | 5,100 | -0,49 % | Valneva: Chikungunya-Impfstoff zeigt über vier Jahre stabile Wirksamkeit | Valneva hat neue Daten zur Antikörperpersistenz seines Chikungunya-Impfstoffs IXCHIQ veröffentlicht. Vier Jahre nach einer einmaligen Impfung zeigten nach Angaben des Biotech-Unternehmens vom Dienstag... ► Artikel lesen |
Das Unternehmen LIMINATUS PHARMA INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,730 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIMINATUS PHARMA INC finden Sie auf Wallstreet Online.